Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

By The Northwire Desk — AI Analysis Mar 10, 2026 · 07:01 TLT · 0.265 Theralase Technologies Inc.
TLT · Price

Executive Summary

  • Theralase® Technologies Inc. closed a non‑brokered private placement of 4,230,770 units at $0.26 CAD per unit, raising gross proceeds of $1,100,000 CAD.
  • Each unit consists of one common share and one warrant to purchase an additional share at $0.36 CAD for five years.
  • Proceeds will fund the Phase II NMIBC clinical study, working capital, and general corporate purposes.

Key Details

  • Units Issued: 4,230,770 units total.
  • Pricing: $0.26 CAD per unit; aggregate gross proceeds of $1,100,000 CAD.
  • Unit Composition: 1 common share + 1 warrant (exercise price $0.36 CAD, exercisable for five years from closing).
  • Use of Proceeds: Phase II non‑muscle invasive bladder cancer (NMIBC) clinical study, working capital, and general corporate purposes.
  • Holding Period: Units subject to a four‑month‑plus‑one‑day hold period under Canadian securities laws, expiring July 11, 2026.
  • Regulatory Conditions: Offering pending final acceptance from the TSX Venture Exchange.
  • Related Party Transaction: 100,000 units (gross proceeds $26,000 CAD) issued to insiders; exempt from formal valuation and minority shareholder approval under MI 61‑101 due to size limits.
  • Closing Timeline: Less than 21 days between filing of material change report and completion of the offering.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Theralase Technologies Inc.

May 29, 2026 · 17:05

Theralase Confirms Bladder Cancer Efficacy Ahead of FDA Filing; Dilution Concerns Weigh on Shares

Earnings May 20, 2026 · 11:07

Theralase Secures Runway for Q3 Regulatory Filing Amidst Dilution Concerns

Financings May 05, 2026 · 19:11

Theralase Secures Runway Amidst Dilution Concerns and Revenue Decline

Financings May 04, 2026 · 17:23

Theralase Confirms Bladder Cancer Submission Timeline Amidst Continued Burn Rate

Earnings Apr 13, 2026 · 07:01

Theralase Preclinical Data Confirms Earlier Findings as Capital Runway Extends

Other Apr 10, 2026 · 07:01

Theralase Secures Runway for Regulatory Filing Amidst Dilutive Financing

Financings